pioglitazone has been researched along with Alcoholism in 4 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Alcoholism: A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schwandt, ML | 1 |
| Diazgranados, N | 1 |
| Umhau, JC | 1 |
| Kwako, LE | 1 |
| George, DT | 1 |
| Heilig, M | 1 |
| Yeligar, SM | 1 |
| Mehta, AJ | 1 |
| Harris, FL | 1 |
| Brown, LAS | 1 |
| Hart, CM | 1 |
| Dieperink, E | 1 |
| Hauser, P | 1 |
| Dockter, K | 1 |
| Miranda, J | 1 |
| Evenson, M | 1 |
| Thuras, P | 1 |
| Blednov, YA | 1 |
| Benavidez, JM | 1 |
| Black, M | 1 |
| Ferguson, LB | 1 |
| Schoenhard, GL | 1 |
| Goate, AM | 1 |
| Edenberg, HJ | 1 |
| Wetherill, L | 1 |
| Hesselbrock, V | 1 |
| Foroud, T | 1 |
| Harris, RA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Role of Proinflammatory Signaling in Alcohol Craving[NCT01631630] | Phase 2 | 16 participants (Actual) | Interventional | 2012-05-31 | Terminated (stopped due to The study was closed to recruitment due to feasibility problems.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 15 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 17.4172 |
| Placebo | 9.8121 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 15 minutes prior to the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 13.7505 |
| Placebo | 8.1871 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 30 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 19.0838 |
| Placebo | 10.5621 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 45 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 18.0838 |
| Placebo | 8.4371 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 5 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 20.5838 |
| Placebo | 9.6871 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 60 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 16.4172 |
| Placebo | 8.9371 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 75 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 15.2505 |
| Placebo | 9.6871 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 90 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 19.2505 |
| Placebo | 8.9371 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 1 hour after the subject received an intravenous bolus of lipopolysaccharide, which occurred on Day 25 or Day 32 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 9.5285 |
| Placebo | 9.1697 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 15 minutes prior to the subject receiving an intravenous bolus of lipopolysaccharide, which occurred on Day 25 or Day 32 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 11.1285 |
| Placebo | 10.7947 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 2 hours after the subject received an intravenous bolus of lipopolysaccharide, which occurred on Day 25 or Day 32 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 11.9285 |
| Placebo | 9.0447 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 3 hours after the subject received an intravenous bolus of lipopolysaccharide, which occurred on Day 25 or Day 32 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 9.5285 |
| Placebo | 10.5447 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 4 hours after the subject received an intravenous bolus of lipopolysaccharide, which occurred on Day 25 or Day 32 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 12.1285 |
| Placebo | 10.5447 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 5 hours after the subject received an intravenous bolus of lipopolysaccharide, which occurred on Day 25 or Day 32 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 12.1285 |
| Placebo | 10.9197 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 6 hours after the subject received an intravenous bolus of lipopolysaccharide, which occurred on Day 25 or Day 32 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 9.9285 |
| Placebo | 9.6697 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 15 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 10 |
| Placebo | 12.125 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 15 minutes prior to the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 10 |
| Placebo | 11.25 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 30 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 10 |
| Placebo | 11.375 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 45 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 10.1667 |
| Placebo | 9.125 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 5 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 10.3333 |
| Placebo | 11.875 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 60 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 10.1667 |
| Placebo | 9.25 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 75 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 10.1667 |
| Placebo | 9.5 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 90 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 10.6667 |
| Placebo | 9.625 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01631630)
Timeframe: Day 1 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 2.8502 |
| Placebo | 4.5791 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01631630)
Timeframe: Day 10 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 3.3403 |
| Placebo | 1.1956 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01631630)
Timeframe: Day 14 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 4.2173 |
| Placebo | 1.2136 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01631630)
Timeframe: Day 17 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 5.0507 |
| Placebo | 1.0706 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01631630)
Timeframe: Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 5.0507 |
| Placebo | 1.6956 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01631630)
Timeframe: Day 24 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 3.884 |
| Placebo | 0.6956 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01631630)
Timeframe: Day 28 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 4.884 |
| Placebo | 1.1125 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01631630)
Timeframe: Day 3 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 5.884 |
| Placebo | 0.5706 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01631630)
Timeframe: Day 31 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 7.2173 |
| Placebo | 1.8206 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01631630)
Timeframe: Day 7 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 3.2897 |
| Placebo | 2.0706 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01631630)
Timeframe: Day 1 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 6.3661 |
| Placebo | 3.2956 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01631630)
Timeframe: Day 10 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 4.7167 |
| Placebo | 0.8687 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01631630)
Timeframe: Day 14 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 4.6366 |
| Placebo | 0.5912 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01631630)
Timeframe: Day 17 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 6.3032 |
| Placebo | 0.8687 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01631630)
Timeframe: Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 5.1366 |
| Placebo | 1.4937 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01631630)
Timeframe: Day 24 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 7.1366 |
| Placebo | 1.1187 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01631630)
Timeframe: Day 28 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 6.4699 |
| Placebo | 1.1228 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01631630)
Timeframe: Day 3 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 5.6366 |
| Placebo | 0.9937 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01631630)
Timeframe: Day 31 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 8.6366 |
| Placebo | 0.8687 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01631630)
Timeframe: Day 7 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 4.9065 |
| Placebo | 0.9937 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01631630)
Timeframe: Day 1 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 7.7503 |
| Placebo | 7.8122 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01631630)
Timeframe: Day 10 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 6.0837 |
| Placebo | 3.9372 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01631630)
Timeframe: Day 14 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 4.7503 |
| Placebo | 4.1872 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01631630)
Timeframe: Day 17 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 4.7503 |
| Placebo | 4.0622 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01631630)
Timeframe: Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 4.417 |
| Placebo | 3.8122 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01631630)
Timeframe: Day 24 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 5.917 |
| Placebo | 2.3122 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01631630)
Timeframe: Day 28 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 6.417 |
| Placebo | 2.6872 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01631630)
Timeframe: Day 3 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 8.417 |
| Placebo | 5.9372 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01631630)
Timeframe: Day 31 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 4.5837 |
| Placebo | 2.8122 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01631630)
Timeframe: Day 7 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 7.0837 |
| Placebo | 4.1872 |
1 trial available for pioglitazone and Alcoholism
| Article | Year |
|---|---|
PPARγ activation by pioglitazone does not suppress cravings for alcohol, and is associated with a risk of myopathy in treatment seeking alcohol dependent patients: a randomized controlled proof of principle study.
Topics: Adult; Alcoholism; Animals; Craving; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Imagi | 2020 |
3 other studies available for pioglitazone and Alcoholism
| Article | Year |
|---|---|
Pioglitazone Reverses Alcohol-Induced Alveolar Macrophage Phagocytic Dysfunction.
Topics: Alcoholism; CCAAT-Enhancer-Binding Protein-beta; Cell Line; Ethanol; Humans; Lung; Macrophages, Alve | 2021 |
Reduced alcohol use in patients prescribed pioglitazone.
Topics: Alcohol Drinking; Alcoholism; Humans; Pioglitazone; Veterans | 2021 |
Peroxisome proliferator-activated receptors α and γ are linked with alcohol consumption in mice and withdrawal and dependence in humans.
Topics: Adult; Alcohol Drinking; Alcoholism; Alkanesulfonates; Animals; Bezafibrate; Brain; Female; Fenofibr | 2015 |